News and Events
Webinar – Integration Site Analysis: An innovative method for faster, more certain clone selection & genetic stability testing
Integration Site Analysis: An Innovative Method For Faster, More Certain Clone Selection & Genetic Stability TestingThis webinar will provide information on the new integration site analysis assay PathoQuest has launched. The assay uses Cas9 targeted DNA cleavage...
Substitution of in vitro and in vivo virus testing with PathoQuest NGS confirmed by French Agency.
Substitution of in vitro and in vivo virus testing with PathoQuest NGS confirmed by French AgencyPathoQuest is pleased to announce that the Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) have recently published their review of PathoQuest’s...
PathoQuest Announces Head-to-Head Study Validating Proprietary Next Generation Sequencing Viral Safety Assay as a Reliable In Vitro Alternative to Animal Testing Methods
PathoQuest Announces Publication of a Head-to-Head Study Validating Proprietary NGS Viral Safety Assay as a Reliable Alternative to Animal Testing NGS assay demonstrated a broader detection range than standard in vivo tests with comparable or higher analytical...
PathoQuest now offering GMP validated NGS Viral Vector Identity test at U.S. site
PathoQuest now offering GMP validated NGS Viral Vector Identity test at U.S. siteWe now offer our GMPÂ validated Viral Vector Identity test at our Wayne, PA site, as well as at our site in Paris, France. Our NGS-based identity test is performed on a short read...
PathoQuest’s Chief Pharmaceutical Officer, Sébastien Renouf, PharmD contributes featured blog post on the ICH Q5A(R2) on Eureka science blog
PathoQuest’s Chief Pharmaceutical Officer, Sébastien Renouf, PharmD contributes featured blog post on the ICH Q5A(R2) on Eureka science blogA new post on Charles River’s Eureka science blog feature’s PathoQuest’s Chief Pharmaceutical Officer, Sébastien Renouf, PharmD,...
Jean-Francois Brepson interviewed for Amazon Web Services (AWS) Health Innovation Podcast
Jean-Francois Brepson interviewed for Amazon Web Services (AWS) Health Innovation PodcastDiscover how PathoQuest enables new biotherapies to be delivered rapidly and safely to patients with its quality testing platform in this episode of the AWS Health Innovation...
PathoQuest has partnered with Amazon Web Services
PathoQuest partners with Amazon Web Services to implement a GMP compliant, cloud-based computing and data storage platformPathoQuest has partnered with Amazon Web Services to implement a cloud-based computing and secure data storage platform that complies with Good...
Oxford Nanopore and PathoQuest announce next step of strategic collaboration
Oxford Nanopore and PathoQuest announce next step of strategic collaboration to bring to market the first sequencing-based quality control test for biopharma genetic characterisation Nanopore sequencing combined with PathoQuest expertise offers a new approach for...
PathoQuest Appoints Dr. Klaus Binder to Company’s Board of Directors
PathoQuest Appoints Dr. Klaus Binder to Company’s Board of DirectorsPathoQuest, the leading expert in GMP next-generation sequencing (NGS) services for biosafety testing, has announced that Klaus Binder, PhD has been appointed as a non-executive director to the...
Video Blog – SENSITIVITY, SCALABILITY AND SPEED: The Value of Next Generation Sequencing (NGS) for Identity Testing of Plasmids & Viral Vectors
Video Blog – SENSITIVITY, SCALABILITY AND SPEED: The Value of Next Generation Sequencing (NGS) for Identity Testing of Plasmids & Viral VectorsIdentity testing is critical for ensuring quality and safety of biopharmaceuticals. As such, identity testing is a key...
Oxford Nanopore and PathoQuest announce the first steps in a strategic collaboration
Oxford Nanopore and PathoQuest announce the first steps in a strategic collaboration to bring the first GMP-accredited, nanopore-based biologics genetic characterisation test to market Nanopore sequencing offers a transformational new approach for robust and accurate...
PathoQuest Reiterates its Strategic Growth Plans by Appointing Daniel Spasic to the Board
PathoQuest Reiterates its Strategic Growth Plans by Appointing Daniel Spasic to the BoardDaniel Spasic, a highly experienced lifescience business leader, has been appointed as a non-executive director to the board of PathoQuest. With over 25 years of hands-on...
PathoQuest Announce the Opening of its New U.S. Facility
PathoQuest Announce the Opening of its New U.S. Facility The Leading Experts in NGS Biosafety Testing and Characterization of Biopharmaceuticals Launch New Capabilities in the Critical U.S. Market Wayne, PA, and Paris, France – October 4, 2022 – PathoQuest, a leader...
A Podcast from Transgene: NGS-Based Biosafety Strategy for Breakthrough Virus-Based Immunotherapies
A Podcast from Transgene: NGS-Based Biosafety Strategy for Breakthrough Virus-Based Immunotherapies Transgene is a French biotech developing virus-based immunotherapies. There manufacturing processes deal with breakthrough therapeutic vaccines highly awaited by...
PathoQuest Appoints Rainer Metzger, Ph.D. as Chairman of the Board of Directors
PathoQuest Appoints Rainer Metzger, Ph.D. as Chairman of the Board of DirectorsPARIS, FRANCE – September 1st, 2022 – PathoQuest, a pioneer of next-generation sequencing (NGS)-based testing solutions for the quality control of biologics, today announced the appointment...
PathoQuest Announces Appointment of Michael Mellor-Clark as Chief Commercial Officer
PathoQuest Announces Appointment of Michael Mellor-Clark as Chief Commercial Officer PARIS, FRANCE, June 23, 2022 – PathoQuest, a leading Contract Research Organization (CRO) for the biosafety testing of biologics with Next-Generation Sequencing (NGS) technologies,...
PathoQuest Appoints Sébastien Renouf, Pharm D., as Chief Pharmaceutical Officer
PathoQuest Appoints Sébastien Renouf, Pharm D., as Chief Pharmaceutical Officer Dr. Sébastien Renouf has almost 20 years of experience in Regulatory Affairs, Risk Management, Quality Assurance, and Safety Control for Cell & Gene Therapy. Before joining...
PathoQuest Appoints Eric Cazergue as Chief Financial Officer
PathoQuest Appoints Eric Cazergue as Chief Financial Officer PARIS, FRANCE — April 06, 2021 – PathoQuest, a pioneer of Next Generation Sequencing (NGS)-based testing solutions for the quality control of biologics, today announced the appointment of Eric Cazergue as...
LOOK FOR US AT THESE UPCOMING MEETINGS
- BioProcess International – September 18th-21st, Boston, MA
- 7th Annual Viral Safety & Viral Clearance Summit – October 3rd-4th, San Francisco, CA
- 8th Bioproduction Congress – October 5th-6th, Lyon, France
- Cell & Gene Meeting on the Mesa – October 10th-12th, Carlsbad, CA
- Festival of Biologics – October 10th-12th, Basel, Switzerland
- European Society of Gene & Cell Therapy (ESGCT) – October 24th-27th, Brussels, Belgium

Contact us
U.S.
466 Devon Park Dr
Wayne, PA 19087
United States
E: contact@pathoquest.com
Sign up for our latest news
France
+33Â (0)1 70 82 17 90
Biopark -Bâtiment B,
11, rue Watt
75013 Paris, France
How can PathoQuest help?
U.S.
466 Devon Park Dr
Wayne, PA 19087
United States
France
+33Â (0)1 70 82 17 90
Biopark -Bâtiment B,
11, rue Watt
75013 Paris, France
E: contact@pathoquest.com
How can PathoQuest help?
Sign up for our latest news